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Introduction: Cyclin-D1, p53 and EGFR are molecular markers that regulate the cell cycle and play an important
role in tumor progression and development. The present study evaluates the prognostic signiﬁcance of these
markers with chemoradiation response in patients of locally advanced oral squamous cell carcinoma (OSCC).
Material andmethod:A total of 97 OSCCpatients (females=19 andmales=78), aged20–67 years and stage III/IV
were recruited. Treatment response was assessed according to WHO criteria. Cyclin-D1, p53 and EGFR expres-
sions in tumor tissue was estimated by immunohistochemical (IHC) method and quantiﬁed as percentage pos-
itive nuclei.
Results: The positive expression rates of molecular markers were 86.6% for Cyclin-D1, 92.8% for EGFR and 85.6%
for p53. The strong positive expressions of both Cyclin-D1 and p53 showed signiﬁcant association with poor re-
sponse. The Cox multivariate regression analysis showed coexpressions of Cyclin-D1 and p53 a signiﬁcant and
independent predictor of overall survival (OR= 1.90, 95% CI= 1.45–4.82, p= 0.046) after adjusting the demo-
graphic, clinicopathological and radiological response. The strong positive expressions of Cyclin-D1 and p53 and
coexpressions of Cyclin-D1, EGFR and p53 showed signiﬁcant (p b 0.05 or p b 0.01 or p b 0.001) and lower sur-
vival as compared to negative or moderate positive expressions and coexpressions, respectively.
Conclusion: Expressions and coexpressions of Cyclin-D1 and p53 may serve as a prognostic marker in OSCC
patients.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Oral squamous cell carcinoma is the sixth most frequent cancer
worldwide. It is a major cause of morbidity and mortality in developing
nations, comprising up to 50% of all malignancies [1,2]. In India a large
fraction of cases occurs in males in their productive years of life. Major-
ity of the cases present in advanced stages, likely related to the poorer
treatment outcome [3].
It emanates from the fact that the clinical course of disease and treat-
ment outcome can also vary in patients with primary tumor from same
site, size and stage, which would be possibly due to poor monitoring of
oral squamous cell carcinoma (OSCC) in the absence of reliable bio-
markers [4,5].erapy, King George's Medical
. Tel.: +91 522 2253316, +91
guptart@gmail.com (S. Gupta).
. This is an open access article underHence a better understanding of the molecular mechanisms and
identiﬁcation of potential oncogenes in oral cancer may provide more
accurate and useful prognostic markers and eventually help us in
achieving the ultimate goal of delivering customized treatment to in-
crease survival at the cost of minimal toxicity which enables the patient
in leading a more productive disease free life [6–8].
Various tumor markers Cyclin-D1, p53, EGFR known to be inhibitors
of apoptosis play crucial roles in the initiation of intracellular signaling
pathwayswhich regulate the activation of cell proliferation, invasion, an-
giogenesis, metastasis and thereby inﬂuence treatment outcome [9–11].
Expressions of these proteins have also been correlated with a more
aggressive phenotype and worse prognosis; nevertheless its signiﬁ-
cance in terms of clinical response and survival has already been exam-
ined in few studies and needs to be further delineated for better
treatment outcome [11–13].
Therefore, identiﬁcation of suitable marker that could provide prog-
nostic assessment of the disease and would help in designing more ap-
propriate and effective treatment strategies for OSCC is warranted, sothe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Demographic and clinico-pathological characteristics of OSCC patients.
Characteristics No. of OSCC patients
(n = 97)
OSCC patients
(%)
Age (years)
≤40 years 28 28.9%
41–60 years 46 47.4%
N60 years 23 23.7%
Sex
Females 19 19.6%
Males 78 80.4%
Site of lesion
Alveolus 15 15.5%
Buccal mucosa 24 24.7%
Cheek 7 7.2%
Hard palate 13 13.4%
Lip 9 9.3%
RMT 13 13.4%
Tongue 16 16.5%
Performance status
Good 42 43.3%
Poor 55 56.7%
Histology
Invasive squamous cell carcinoma 34 35.1%
Squamous cell carcinoma 63 64.9%
Grade
Moderately differentiated (MD) 26 26.8%
Poorly differentiated (PD) 6 6.2%
Well differentiated (WD) 65 67.0%
Size
T2 2 2.1%
T3 22 22.7%
T4 73 75.3%
Nodal status
N0 32 33.0%
N1 32 33.0%
N2 33 34.0%
Stage
III 28 28.9%
IV 69 71.1%
12 H. Khan et al. / BBA Clinical 3 (2015) 11–17that limited resources available to patients can be conserved and undue
treatment can be avoided.
The current study is hence proposed to assess the combined expres-
sions of Cyclin-D1, EGFR and p53 and its prognostic signiﬁcance with
treatment response in oral cancer patients undergoing chemoradiation.
2. Material and method
A total of 97 histologically proven cases of locally advanced stages
(III, IV) oral cancer withW.H.O. performance status of grade 0/1 attend-
ing radiotherapy O.P.D. at K.G. Medical University, Lucknow (UP), India,
in the years 2009–2012 were enrolled in the study. These cases were
assessed thoroughly (history, clinical examination and investigations).
The study was approved by the ethics committee of the K.G. Medical
University, andwritten informed consentwas obtained fromall patients
before enrollment.
All the patients were given 2 cycles of induction taxol
(175 mg/m2 day 1) and cisplatin (50 mg/m2 day 2) chemotherapy
and were subjected for radiation along with concurrent cisplatin
(35 mg/m2) 4-weeks from the completion of induction chemotherapy.
Radiotherapy was given by External beam Conventional Method
(200 CGy/fraction to a total dose of 70 Gy in 35 fractions in 7 weeks
by cobalt60 to primary tumor site and neck.
The protocol plan was continued despite mucositis or dermatitis.
However, the dose of cisplatin was reduced to 50% if the calculated cre-
atinine clearance level was 30–50 ml/min. No cisplatin was given if the
creatinine clearance level was less than 30 ml/min. In the presence of
myelosuppression (WBC count b 4000/mm3 or platelets count less
than 100,000/mm3), persistent fever that exceeded 38 °C or other clin-
ically apparent infections, chemoradiationwas postponed for 1 week or
interrupted.
For histopathological and immunohistochemical studies, tumor
samples from the lesion site were ﬁxed in 10% buffered formalin
and then embedded in parafﬁn. Parafﬁn embedded formalin ﬁxed tis-
sues were processed and routine H and E stained sections were eval-
uated to conﬁrm the diagnosis of squamous cell carcinoma and to
grade the lesion. Further sections were processed for Cyclin-D1,
EGFR and p53 biomarkers by immunohistochemistry (IHC) using
primary monoclonal antibodies and a polymer based secondary anti-
body detection kit from Dakopatts, Denmark. Standard immunohisto-
chemistry protocol was used. In short deparafﬁnized rehydrated
sections were blocked for endogenous peroxidases in 0.3% hydrogen
peroxide in methanol, followed by a rinse in distil water. Antigen re-
trieval was achieved at 121 °C in 10 mM citrate buffer (pH 6.0) for
10 min using Pascal retrieval system from Dakopatts, Denmark. Slides
cooled to room temperature were washed thrice with TBS and there-
after incubated overnight at 4 °C with Primary Antibodies to Cyclin-
D1 (Dakopatts Denmark), p53 (DO7, Leica Microsystems, Germany)
and EGFR (BioGenex, USA). After washing with Tris-buffered saline,
the sections were incubated for 30 min with secondary antibody.
Cyclin-D1, EGFR and p53 were visualized with DAKO Liquid Diamino-
benzidine substrate chromogen and counterstained with diluted
Mayer's hematoxylin. Sections mounted with DPX were inspected
under a Zeiss Z2 imager and photographed at 40× magniﬁcation.
The immunohistochemical evaluation was carried out in tumor
hotspots including the invasion front, which was regarded as most in-
dicative of the biological activity of the tumor, in 10 high power ﬁelds.
About 1500–2000 tumor cells were observed in all tumors at a magniﬁ-
cation of 40× in 10 selected ﬁelds. For EGFR and Cyclin-D1 tumors were
labeled as negative if b10%, moderate positive between 10 and 50% and
strongly positive if N50%, tumor cells expressed the antigen [14,15]. p53
expression was evaluated as negative if b10%, moderate positive be-
tween 10 and 25% and strongly positive if N25% [16].
Assessment of tumor response was done by clinical examination,
radiological investigations (CT-scan) 4–6 weeks after completion of
treatment. Biopsy or ﬁne needle aspiration cytology to determinepathological response was not performed routinely; it was done only
in the case of partial response/suspected lesion to conﬁrm the presence
of disease. After chemoradiation, patients were followed up to 2 years.
The deﬁnitions of treatment response viz. complete response (CR),
partial response (PR) and no response (NR) [stable disease (SD) +
progressive disease (PD)] were based on the standard deﬁnitions
established by World Health Organization [33].
The end point was to evaluate clinical beneﬁts of chemoradiation on
response rate, 2 year overall survival (OS) and prognostic signiﬁcance of
Cyclin-D1, EGFR and p53 expressions with OS in locally advanced squa-
mous cell carcinoma of oral cavity.
2.1. Statistical analysis
Continuous data were summarized as Mean ± SD while discrete
(categorical) in no and %. Categorical groups were compared by chi-
square (χ2) test. Groups were also compared by one way analysis of
variance (ANOVA) and the signiﬁcance of themean difference between
the groupswas done by Tukey's post hoc test. Cox's univariate andmul-
tivariate hazard regression analyses were done to assess the predictors
of overall survival. Survival between the two groupswas compared by a
Kaplan–Meiermethod using Log-rank test. A two-sided (α=2)p b 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Basic characteristics of OSCC patients
The basic characteristics (demographic and clinico-pathological) of
OSCC patients at presentation are summarized in Table 1. The age of
Fig. 1.Microphotograph showing immunohistochemical expression of Cyclin-D1 in OSCC (A) showing negative nuclei (B) showing positive stained nuclei (C) showing strongly positive
stained nuclei (DAB × 125 × digital magniﬁcation).
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years. Among patients, mostly 41–60 years aged (47.4%), mostly males
(80.4%), mostly had lesion at buccal mucosa (24.7%) and mostly with
poor performance status (56.7%). The histology of most of the patients
was squamous cell carcinoma (64.9%), mostly with well differentiated
grade (67.0%), tumor size T4 (75.3%), nodal status N2 (34.0%) and
tumor stage IV (71.1%).
3.2. Molecular marker expressions and correlation
The immunohistochemical expressions of molecular markers EGFR,
p53 and Cyclin-D1 were shown in Figs. 1, 2 and 3 respectively. The ex-
pressions of molecular markers and their correlation in OSCC patients
are summarized in Tables 2 and 3, respectively. The positive expression
rates of molecular markers were 86.6% for Cyclin-D1, 92.8% for EGFR
and 85.6% for p53 (Table 2). Further, molecular marker expressions of
Cyclin-D1 and p53 showed a signiﬁcant correlation with each other
(χ2= 29.27, p b 0.001); however, no statistically signiﬁcant association
was found between Cyclin-D1 and EGFR (χ2 = 2.56, p = 0.634) and
EGFR and p53 (χ2 = 8.59, p = 0.072) (Table 3).
3.3. Association of molecular marker expressions with clinicopathological
features
The associations betweenmolecularmarker expressions and clinico-
pathological features of OSCC patients are summarized in Table 4. The
molecular marker expressions of both Cyclin-D1 (χ2 = 6.39, p =
0.041) and p53 (χ2 = 8.20, p = 0.017) showed signiﬁcant association
with nodal status. However, molecular marker expressions did not
(p N 0.05) show signiﬁcant associations with grade, tumor size and
stage.Fig. 2.Microphotograph showing immunohistochemical expression of EGFR in OSCC (A) show
membranous staining (C) showing strongly positive cytoplasmic and membranous staining (D3.4. Association between molecular marker expression levels and
radiological response
The association between molecular marker expression levels (%)
and radiological response is summarized graphically in Fig. 4. According
to radiological response, 30 (30.9%) patients had complete response
(CR), 51 (52.6%) had partial response (PR) and 16 (16.5%) had no re-
sponse (NR).
Fig. 4 showed that as mean molecular marker expression levels in-
crease, radiological response becomes poorer. Comparing the expres-
sion levels among the radiological response groups, ANOVA revealed
signiﬁcantly different expression levels of Cyclin-D1 (F = 22.85, p b
0.001) and p53 (F = 87.16, p b 0.001) among the groups. Further,
Tukey's test also revealed signiﬁcantly (p b 0.05 or p b 0.001) different
and higher mean expression levels of both Cyclin-D1 and p53 in both
PR and NR as compared with CR. Furthermore, the mean expression
levels of both Cyclin-D1 and p53 were also signiﬁcantly (p b 0.001) dif-
ferent and higher in NR as compared with PR. However, the mean ex-
pression level of EGFR did not show a signiﬁcant association with
radiological response.
Further, strong positive expressions of both Cyclin-D1 (χ2 = 27.92,
p b 0.001) and p53 (χ2= 69.40, p b 0.001) also showed a signiﬁcant as-
sociationwith a poor responsewhile strong positive expression of EGFR
showed a signiﬁcant association with a partial response (χ2 = 12.44,
p = 0.014) (Table 5).3.5. Association of molecular marker expressions and coexpressions with
survivals
TheOSCC patientswere followed up for two years (24months). Dur-
ing the period, 19 patients died due to disease (19.6%), 67 were liveing negative cytoplasmic and membranous staining (B) showing positive cytoplasmic and
AB × 125 × digital magniﬁcation).
Fig. 3.Microphotograph showing immunohistochemical expression of Cyclin-D1 in OSCC (A) showing negative nuclei (B) showing positive stained nuclei (C) showing strongly positive
stained nuclei (DAB × 125 × digital magniﬁcation).
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(live + LTF) patients was 80.4%.
The univariate (unadjusted) Cox regression analysis found molecu-
lar marker expressions of both Cyclin-D1 and p53 and coexpressionsTable 2
Frequency distribution of molecular marker expressions of OSCC patients (n = 97).
Expression Cyclin-D1 (n = 97)
(%)
EGFR (n = 97)
(%)
p53 (n = 97)
(%)
Negative 13 (13.4) 7 (7.2) 14 (14.4)
Moderate positive 64 (66.0) 59 (60.8) 62 (63.9)
Strong positive 20 (20.6) 31 (32.0) 21 (21.6)
Total positive 84 (86.6) 90 (92.8) 83 (85.6)
Table 3
Correlation between Cyclin-D1, EGFR and p53 expressions in OSCC patients (n = 97).
Molecular marker n Cyclin-D1
Negative
(n) (%)
Moderate positive
(n) (%)
Strong positive
(n) (%)
EGFR
Negative 7 1 (14.3) 6 (85.7) 0 (0.0)
Moderate positive 59 9 (15.3) 37 (62.7) 13 (22.0)
Strong positive 31 3 (9.7%) 21 (67.7) 7 (22.6)
p53
Negative 14 1 (7.1) 12 (85.7) 1 (7.1)
Moderate positive 62 11 (17.7) 45 (72.6) 6 (9.7)
Strong positive 21 1 (4.8) 7 (33.3) 13 (61.9)
Table 4
Association between molecular marker expressions and clinicopathological features in OSCC p
Clinicopathological
features
Cyclin-D1 EGFR
Negative
(n = 13) (%)
Moderate
positive
(n = 64) (%)
Strong
positive
(n = 20) (%)
p
value
Negative
(n = 7) (%)
Mod
posi
(n =
Grade
MD/PD 5 (38.5) 20 (31.3) 7 (35.0) 0.861 3 (42.9) 19 (
WD 8 (61.5) 44 (68.8) 13 (65.0) 4 (57.1) 40 (
Tumor size
T2/T3 4 (30.8) 16 (25.0) 4 (20.0) 0.780 1 (14.3) 18 (
T4 9 (69.2) 48 (75.0) 16 (80.0) 6 (85.7) 41 (
Nodal status
N0 6 (46.2) 24 (37.5) 2 (10.0) 0.041 2 (28.6) 23 (
N1/N2 7 (53.8) 40 (62.5) 18 (90.0) 5 (71.4) 36 (
Stage
III 6 (46.2) 19 (29.7) 3 (15.0) 0.151 2 (28.6) 20 (
IV 7 (53.8) 45 (70.3) 17 (85.0) 5 (71.4) 39 (of Cyclin-D1 and p53, and EGFR and p53 the signiﬁcant (p b 0.05 or
p b 0.01) predictors of overall survival in OSCC patients (Table 6).
The multivariate (adjusted) Cox regression analysis revealed the
coexpressions of Cyclin-D1 and p53 a signiﬁcant (p b 0.05) and inde-
pendent predictor of overall survival in OSCC patients after adjusting
the demographic (age, sex and performance status), clinicopathological
features (site, histology, grade, size, nodal status and stage) and radio-
logical response (Table 6).
The two year overall survival of OSCC patients was also done
according to molecular marker expressions and coexpressions and
summarized graphically in Fig. 5. The strong positive expressions of
both Cyclin-D1 (χ2 = 17.70, p b 0.001) and p53 (χ2 = 35.79, p b
0.001) showed signiﬁcant and lower survivals as compared with nega-
tive or moderate positive expressions. Further, the strong positiveEGFR
p value Negative
(n) (%)
Moderate positive
(n) (%)
Strong positive
(n) (%)
p value
0.634
b0.001 0 (0.0) 12 (85.7) 2 (14.3) 0.072
7 (11.3) 32 (51.6) 23 (37.1)
0 (0.0) 15 (71.4) 6 (28.6)
atients (n = 97).
p53
erate
tive
59) (%)
Strong positive
(n = 31) (%)
p value Negative
(n = 14) (%)
Moderate
positive
(n = 62) (%)
Strong
positive
(n = 21) (%)
p
value
32.2) 10 (32.3) 0.847 6 (42.9) 22 (35.5) 4 (19.0) 0.267
67.8) 21 (67.7) 8 (57.1) 40 (64.5) 17 (81.0)
30.5) 5 (16.1) 0.259 6 (42.9) 12 (19.4) 6 (28.6) 0.165
69.5) 26 (83.9) 8 (57.1) 50 (80.6) 15 (71.4)
39.0) 7 (22.6) 0.281 9 (64.3) 19 (30.6) 4 (19.0) 0.017
61.0) 24 (77.4) 5 (35.7) 43 (69.4) 17 (81.0)
33.9) 6 (19.4) 0.351 6 (42.9) 16 (25.8) 6 (28.6) 0.445
66.1) 25 (80.6) 8 (57.1) 46 (74.2) 15 (71.4)
Fig. 4. Association betweenmolecular marker expression levels and radiological response
inOSCC patients (A) showing association of NRwith strong positive expressions of Cyclin-
D1 alongwith highermean expression levels of Cyclin-D1 in both PR and NR as compared
with CR (B) showing association of PR and NR with an increase in levels of EGFR expres-
sion as compared with CR (C) showing a signiﬁcant association of NRwith strong positive
expressions of p53 along with higher mean expression levels of p53 in both PR and NR as
compared with CR.
Table 5
Association betweenmolecularmarker expressions and radiological response in OSCC pa-
tients (n = 97).
Molecular marker expressions n Radiological response p value
CR (n) (%) PR (n) (%) NR (n) (%)
Cyclin-D1
Negative 13 4 (30.8) 8 (61.5) 1 (7.7) b0.001
Moderate positive 64 24 (37.5) 36 (56.3) 4 (6.3)
Strong positive 20 2 (10.0) 7 (35.0) 11 (55.0)
EGFR
Negative 7 3 (42.9) 3 (42.9) 1 (14.3) 0.014
Moderate positive 59 24 (40.7) 24 (40.7) 11 (18.6)
Strong positive 31 3 (9.7) 24 (77.4) 4 (12.9)
p53
Negative 14 12 (85.7) 2 (14.3) 0 (0.0) b0.001
Moderate positive 62 16 (25.8) 44 (71.0) 2 (3.2)
Strong positive 21 2 (9.5) 5 (23.8) 14 (66.7)
CR = complete response, PR = partial response, NR = No response.
Table 6
Association between molecular marker expressions and coexpressions with overall sur-
vivals in OSCC patients (n = 97) using Cox regression analysis.
Molecular marker
expressions and
coexpressions
Univariate (unadjusted)
Cox regression analysis
Multivariate (adjusted)
Cox regression analysis
OR (95% CI) p value OR (95% CI) p value
Cyclin-D1
Negative Ref Ref
Moderate positive 0.56 (0.29–1.18) 0.136 0.80 (0.33–1.94) 0.624
Strong positive 0.59 (0.35–0.98) 0.041 0.98 (0.45–2.13) 0.954
EGFR
Negative Ref Ref
Moderate positive 0.58 (0.25–1.32) 0.191 0.55 (0.21–1.43) 0.217
Strong positive 1.14 (0.74–1.77) 0.548 1.45 (0.87–2.42) 0.156
p53
Negative Ref Ref
Moderate positive 0.39 (0.20–0.77) 0.007 0.86 (0.25–2.92) 0.802
Strong positive 0.61 (0.37–1.01) 0.053 1.12 (0.45–2.75) 0.809
Cyclin-D1 & EGFR
Negative Ref Ref
Moderate positive 0.67 (0.39–1.16) 0.154 0.63 (0.33–1.20) 0.160
Strong positive 0.81 (0.52–1.27) 0.359 1.19 (0.68–2.09) 0.540
Cyclin-D1 & p53
Negative Ref Ref
Moderate positive 0.43 (0.25–0.76) 0.028 0.69 (0.31–1.54) 0.360
Strong positive 1.58 (1.35–2.94) 0.003 1.90 (1.45–4.82) 0.046
EGFR & p53
Negative Ref Ref
Moderate positive 0.51 (0.30–0.86) 0.012 0.65 (0.30–1.41) 0.275
Strong positive 1.07 (0.68–1.69) 0.764 1.54 (0.87–2.72) 0.142
15H. Khan et al. / BBA Clinical 3 (2015) 11–17coexpressions of Cyclin-D1 and EGFR (χ2= 6.23, p= 0.044), Cyclin-D1
and p53 (χ2 = 23.96, p b 0.001), and EGFR and p53 (χ2 = 10.45, p b
0.005) also showed signiﬁcant and lower survivals as compared with
negative or moderate positive coexpressions. Furthermore, the strong
positive coexpressions of all three markers also showed a signiﬁcant
and lower survival as compared with negative or moderate positive
coexpressions (χ2 = 11.84, p = 0.003).
4. Discussion
In this study, immunohistochemistry was used to evaluate Cyclin-
D1, EGFR and p53 expressions in oral cancer. Chemoradiation is the
basis of treatment in oral cancer worldwide, but the overall response
rate is only about 30%, which may vary among individuals [17]. The
study of cancer biology of OSCC can help in the molecular proﬁling oftumor markers that might predict the clinical behavior of the tumor,
which is not strictly related to stage or histological grading as it is still
not clear why some patients do better than others with the same
stage and site of disease.
Cyclins, cyclin-dependent kinases, GSK3, cyclin-dependent kinase
inhibitors and AKT1, AKT2, AKT3 kinases have emerged as critical medi-
ators of signal transduction pathways downstream of activated tyrosine
kinases and phosphatidylinositol 3-kinase are involved in the regulation
of cell cycle progression and prevention of apoptosis. These are known
to be associated with tumor genesis and resistance to apoptosis making
the tumor refractory to treatment [18–20]. Various studies have report-
ed a positive correlation between Cyclin-D1 protein expression and
stage, lymph node involvement and reduced survival but did not
reach statistical signiﬁcance [21]. In this study, Cyclin-D1 expression in
oral cancer was observed 92%, which is higher than the 19% reported
for head and neck cancer which could be the potential targets for over-
coming the treatment resistance.
Elevated EGFR expression in oral squamous cell carcinomas have
also been associated with larger tumor and advanced stage and hence,
a poor prognosis [22,23]. EGFR activation by ligand binding leads to
Fig. 5. Overall survival proportions of OSCC patients according to marker expressions and coexpressions showing association of strong positive expressions of Cyclin-D1, EGFR, P53 and
coexpressions of Cyclin-D1/EGFR, Cyclin-D1/p53, EGFR/ p53 and Cyclin-D1/EGFR/ p53 with lower survivals as compared with negative or moderate positive expressions and
coexpressions.
16 H. Khan et al. / BBA Clinical 3 (2015) 11–17parallel signalingmainly through Ras,MAPK/MAPK-extra cellular signal
regulated kinase, phosphatidylinositol-3 kinase/AKT phospholipase
protein kinase α and signal transducer and activator 3 pathways [24,
25]. Activation of these pathways ultimately leads to transcription of
other genes responsible for cell growth, differentiation and death.
EGFR overexpression and aberrant EGFR gene copy number have been
associated with poorer prognosis and disease-speciﬁc survival in
SCCHN. Our study has also shown signiﬁcance of EGFR as a high risk in-
dicator for disease progression and propagation.
Among the genes related to oral cancer, p53 has been one of the
most frequently studied. Abnormal p53 function has been detected in33–100% of head and neck cancer specimens, depending on the sources
of tissue and method of detection. p53 may participate in cellular path-
ways leading to apoptosis following treatment with DNA-damaging
agents such as cisplatin [26]. Our data indicate that abnormal overex-
pression of p53 protein is a strong indicator of poor prognosis. Similar
data have been demonstrated in bladder cancer where abnormal p53
overexpression has also been found to be associated with decreased
survival [24].
Mutations of the tumor suppressor gene p53 are themost signiﬁcant
events in several human cancers [27,32]. Various studies have docu-
mented that more than 90% of the p53 gene mutations in SCCHN in
17H. Khan et al. / BBA Clinical 3 (2015) 11–17general aremissensemutations, which are caused by a change in amino
acid and a probable increase in the stability of the protein [28] which
can be detected by immunohistochemical analysis due to stability of
the protein [28,29].
Studies have also strongly documented the correlation between the
immunohistochemical overexpression of p53 protein and the presence
of missense mutations within the p53 gene. Further, overexpression of
p53 has been associated with poor survival in a number of studies
[30–32].
In the present study, we have also found poor survival in patients
where Cyclin-D1 and p53 were overexpressed as compared with mod-
erate or negative expression, suggesting the possibility of occurrence of
missense mutation in these patients and documenting the prognostic
role of overexpressed p53 in OSCC. Thus, it is imperative to validate
the IHC overexpressions of molecular markers with mutation analysis.
This is also the drawback of the present study.
Thereforemonitoring andmanipulation of signal transduction path-
way which forms the basis of treatment resistance to treatment may
have important implications for the management of cancer. Direct
targeting and inhibition of this pathway may increase radiosensitivity
by antagonizing the radiation induced cellular defense mechanisms es-
pecially in tumors that have activated the PI3-K/AKT cascade. More im-
portantly, speciﬁc targeting of this pathway in combination with
radiotherapy or chemotherapy may enhance tumor control by antago-
nizing cellular defense in response to treatment.
Although manymarkers have been studied and have given new un-
derstanding of cancer pathogenesis and progression as a potential con-
tributor tomultistep process of oncogenesis they are not yet ready to be
used as prognostic signiﬁcance in routine clinical investigative and ther-
apeutic procedures in patientswith these tumors. Tumor stage, patient's
age and performance status still remains the basis for therapeutic deci-
sions. In view of this further studies are needed urgently to understand
and delineatemore speciﬁc and sensitive markers aiding in tumor diag-
nosis, prediction and prognostication of treatment modality to enhance
the magnitude of treatment outcome in terms of response and survival
of patients with these tumors.
5. Conclusion
The expressions of Cyclin-D1 and p53 and coexpressions of Cyclin-
D1, EGFR and p53may serve as prognosticmarkers in patients of locally
advanced oral squamous cell carcinoma. The ﬁndings of molecular
marker expressions may need further validations of mutation analysis.
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